RESEARCH LITERACY / SOURCE NOTES
TB-500 versus thymosin beta-4: check molecular identity
Do not assume a material labelled TB-500 is interchangeable with full-length thymosin beta-4. Establish the exact sequence and modification before applying evidence from one material to another.
Editorial draft · primary sources linked; not independently clinically reviewed.
Editorial update:
What was actually identified?
A 2012 analytical investigation identified Ac-LKKTETQ, an acetylated thymosin beta-4 fragment, in the product it tested. A label name alone therefore cannot establish the molecular identity of another sample.
- Esposito et al., 2012 — analytical identification of a TB-500 fragment ↗Identification of one tested product; not a treatment trial or a definition of every market-labelled product.
Why the distinction changes the evidence
Research on thymosin beta-4 ophthalmic solution concerns an eye formulation and a defined study population. It cannot establish that injecting a fragment improves musculoskeletal recovery. Route, formulation and molecule must stay attached to the finding.
- Sosne and Ousler, 2015 — thymosin beta-4 ophthalmic phase 2 trial ↗Ophthalmic formulation; cannot establish efficacy of injected fragments.
What to compare on a document
Look for the explicit sequence, terminal modifications, expected mass, method and tested sample identifier. If the report provides only the label “TB-500”, note the unresolved identity rather than silently assigning the evidence for another molecule.
Ask the issuing laboratory what its identity conclusion covers. A software reader should flag an ambiguity, not resolve it from a supplier’s product title.
What about dosage?
Neither this identity comparison nor an analytical identification paper establishes a human treatment dose. Do not combine a fragment identity result with an unrelated full-length study to create a protocol.
Our compound profile preserves separate human, preclinical and uncertainty sections. Regulatory discussion or advisory consideration is not approval of every material using the name.
- FDA — July 2026 Pharmacy Compounding Advisory Committee materials ↗Dated advisory proceedings; discussion/recommendations are not product approval.